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Alzheimerís disease (AD) is said to be the
leading cause of dementia in elderly individuals.
The neuropathologic hallmarks of this illness are the
presence of extracellular deposits of β-amyloid pep-
tide as fibril aggregates that form neurotic plaques
and intracellular neurofibrillary tangles. Neuro-
chemically AD is characterized by a consistent
deficit in cholinergic neurotransmission, particular-
ly affecting cholinergic neurons in specific regions
of the brain (1, 2). Due to several theoretical possi-
bilities of AD therapy, the earliest (clinically rele-
vant) approach is using acetylcholinesterase
inhibitors (AChEIs). This finding resulted in the
introduction of 1,2,3,4-tetrahydro-9-aminoacridine
(tacrine) as the first AChEI, specifically approved
for the treatment of AD (3). Currently, three
cholinesterase inhibitors such as donepezil (4),
galantamine (5) and rivastigmine (6) are widely
used for the symptomatic treatment of patients with
mild-to-moderate AD. These drugs represent differ-
ent chemical classes of compounds and exhibit dif-
ferent selectivity for both cholinesterases, acetyl-
cholinesterase (AChE) and butyrylcholinesterase
(BuChE). Rivastigmine is an inhibitor of both
enzymes, whereas donepezil and galantamine are
inhibitors of AChE alone. Tacrine, because of its
hepatotoxicity, is not used in clinical practice; it is
used as reference inhibitor of both enzymes.
Currently, some investigations indicated that
BuChE could also play a significant role in the reg-
ulation of acetylcholine in the human brain.
Therefore, compounds which inhibit BuChE may
also provide added benefits in the therapy of AD. It
is known that BuChE is mainly associated with glial
cells and it is found in much lower concentrations
than AChE in the healthy brain. However, over the
course of AD, AChE activity progressively decreas-
es, while BuChE activity increases and BuChE may
act as a compensatory mechanism for acetylcholine
metabolism (7, 8). Consequently, with AD progress,
AChE regulation may become increasingly depend-
ent on BuChE, and dual inhibitors may provide
more sustained efficacy than AChE selective agent. 
As part of our studies (9) aimed at the development
of cholinesterase inhibitors a series of N-benzyl sub-
situted amides of 1H-indole-5-carboxylic acid deriv-
atives (6añf) was synthesized. The designed struc-
tures contain pharmacophoric N-benzylpiperidine
moiety connected by amide group with heteroaro-
matic indole fragment. The benzylpiperidine frag-
ment of molecules designed is based on donepezil
structure and is a very well known fragment in
numerous AChE inhibitors (Fig. 1) (9ñ11).
It was assumed that the molecules designed
might interact with both the catalytic anionic site
(CAS) and the peripheral anionic site (PAS) of the
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enzyme. In the present study, the synthesis of new
N-benzyl substituted piperidine amides of 1H-
indole-5-carboxylic acid and their in vitro biological




As a starting material for the synthesis the final
amides, piperidin-4-ol (1) was chosen. In the first
step, compound (1) reacted under the phase transfer
catalysis conditions with appropriate substituted
benzylbromide derivatives (2añf), giving relevant
N-benzylpiperidin-4-ol derivatives (3añf) with good
to excellent (72ñ99%) yields. These reactions were
carried out in the mixture of acetonitrile, K2CO3 and
tetrabutylammonium iodide. In the next step, the
obtained alcohols (3añf) were transformed into rele-
vant substituted 2-(1-benzylpiperidin-4-yl)isoindo-
line-1,3-dione derivatives (4añf) in the Mitsunobu
reaction (12), which was carried out in dry THF
Figure 1. Donepezil and AChE inhibitors (4, 9ñ11)
Figure 2. Schematic structure of compounds design
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using phtalimide, triphenylphosphine (Ph3P) and
diisopropylazodicarboxylate (DIAD) under argon
atmosphere. The yields of this process were rather
low between 17 and 31%. Hydrazinolysis of com-
pounds (4añf) gave primary amines (5añf), which
have been used for further synthesis without purifi-
cation. Finally, the commercially available 1H-
indole-5-carboxylic acid was activated with car-
bonyldiimidazole (CDI) and reacted with the appro-
priate amine (5añf) in dry THF (13) giving the final
compounds (6añf) with low to good yield (6c)
(25ñ85%). The structures of the new compounds
were confirmed by elemental analysis and spectral
data (1H NMR, MS), their purity by thin layer chro-
matography.
Reagents and solvents were purchased from
common commercial suppliers, and were used with-
out further purification. All experiments, in which
air-sensitive materials were used, were carried out in
oven-dried glassware under a dry argon atmosphere.
Standard vacuum techniques were used for handling
air-sensitive materials. Tetrahydrofuran (THF) was
dried, kept under argon and freshly distilled over
sodium-benzophenone before use. Melting points
were determined in open capillaries on an
Electrothermal 9300 apparatus and are uncorrected.
Merck silica gel 60 (70ñ230 mesh ASTM) was used
for column chromatography. As solvents for chro-
matography mixtures: S1 dichloromethane/methanol
(9:1), S2 dichloromethane/methanol (95:5), S3 ace-
tone, were used. Analytical thin layer chromatogra-
phy was performed on Merck TLC plates, silica gel
60 F254. TLC visualization was achieved with a UV
lamp or ninhydrin solution (0.3% ninhydrin in n-
BuOH with 3% AcOH). Nuclear magnetic reso-
nance spectra (1H NMR) were recorded with Varian
Mercury VX 300 MHz (Hansen Way, USA) spec-
trometer using CDCl3 or DMSO-d6 at ambient tem-
perature using the solvent signal as an internal stan-
dard. The chemical shifts (δ) are reported in parts
per million (ppm). In the case of solid products ele-
mental analyses were performed on Vario EL III
Elemental analyzer (Elementar Analysensystem,
Hanau, Germany). Mass spectras were recorded on
Waters Acquity TQD spectrometer (Waters, USA).
Mass spectra were obtained by electronic impact
(EI) at 70 eV.
General procedure for the synthesis of com-
pounds 3añf
Piperidin-4-ol (1) (2.03 g, 20 mmol) and rele-
vant benzylbromide derivatives (2añf) (20 mmol)
were dissolved in 20 mL of acetonitrile. Then, anhy-
drous K2CO3 (2.76 g, 20 mmol) and TBAI (0.08 g,
0.2 mmol) were added. The reaction mixture was
refluxed for 24 h. The inorganic salt was filtered and
washed with methanol. The filtrate was evaporated
and the oil obtained was purified by column chro-
matography using a mixture of dichloromethane/
methanol (9:1).
1-Benzylpiperidin-4-ol (3a)
Yellow oil. Yield: 72%; TLC: Rf = 0.36 (S1);
1H NMR (CDCl3, δ, ppm): 1.22 (s, CHOH, 1H),
1.51ñ1.69 (m, piper, 2H), 1.82ñ1.95 (m, piper, 2H),
2.09ñ2.22 (m, piper, 2H), 2.69ñ2.82 (m, piper, 2H),
3.51 (s, NCH2, 2H), 3.62ñ3.77 (m, CHOH, 1H),
7.19ñ7.36 (m, arom, 5H).
1-(3-Bromo)benzylpiperidin-4-ol (3b)
Yellow oil. Yield: 99%; TLC: Rf = 0.50 (S1);
1H NMR (CDCl3, δ, ppm): 1.49ñ1.68 (m, CHOH,
piper, 3H), 1.80ñ1.94 (m, piper, 2H), 2.07ñ2.21 (m,
piper, 2H), 2.66ñ2.79 (m, piper, 2H), 3.47 (s, NCH2,
2H), 3.64ñ3.75 (m, CHOH, 1H), 7.12ñ7.50 (m,
arom, 4H).
1-(3-Chloro)benzylpiperidin-4-ol (3c)
Yellow oil. Yield: 90%; TLC: Rf = 0.41 (S1);
1H NMR (CDCl3, δ, ppm): 1.50ñ1.70 (m, CHOH,
piper, 3H), 1.82ñ1.94 (m, piper, 2H), 2.08ñ2.22 (m,
piper, 2H), 2.67ñ2.79 (m, piper, 2H), 3.47 (s, NCH2,
2H), 3.63ñ3.76 (m, CHOH, 1H), 7.14ñ7.35 (m,
arom, 4H).
1-(3-Fluoro)benzylpiperidin-4-ol (3d)
Yellow oil. Yield: 86%; TLC: Rf = 0.46 (S1);
1H NMR (CDCl3, δ, ppm): 1.51ñ1.68 (m, piper, 2H),
1.82ñ1.96 (m, CHOH, piper, 3H), 2.10ñ2.23 (m,
piper, 2H), 2.68ñ2.80 (m, piper, 2H), 3.49 (s, NCH2,
2H), 3.62ñ3.77 (m, CHOH, 1H), 6.88ñ7.31 (m,
arom, 4H).
1-(3-Methoxy)benzylpiperidin-4-ol (3e)
Yellow oil. Yield: 98%; TLC: Rf = 0.20 (S1);
1H NMR (CDCl3, δ, ppm): 1.51ñ1.67 (m, CHOH,
piper, 3H), 1.82ñ1.94 (m, piper, 2H), 2.09ñ2.24 (m,
piper, 2H), 2.69ñ2.83 (m, piper, 2H), 3.48 (s, NCH2
arom, 2H), 3.64ñ3.75 (m, CHOH, 1H), 3.80 (s,
OCH3, 3H), 6.75ñ7.28 (m, arom, 4H).
1-(4-Bromo)benzylpiperidin-4-ol (3f)
Yellow oil. Yield: 98%; TLC: Rf = 0.40 (S1);
1H NMR (CDCl3, δ, ppm): 1.49ñ1.73 (m, CHOH,
piper, 3H), 1.80ñ1.94 (m, piper, 2H), 2.07ñ2.21 (m,
piper, 2H), 2.66ñ2.77 (m, piper, 2H), 3.47 (s, NCH2,
2H), 3.62ñ3.77 (m, CHOH, 1H), 7.14ñ7.48 (m,
arom, 4H).
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General procedure for the synthesis of com-
pounds 4añf
To the stirred solution of Ph3P (6.4 g, 24 mmol)
in dry THF (150 mL), maintained at 0OC under an
atmosphere of dry argon, DIAD (4.4 g, 20 mmol)
was added dropwise. The resulting solution was
stirred at the same temperature for 20 min where-
upon it showed a creamy white color. Then, relevant
1-benzylpiperidin-4-ol (3añf) (20 mmol) dissolved
in THF (26 mL) was added dropwise. Finally,
phthalimide (3.28 g, 20 mmol) was added in one
portion. The resulting mixture was stirred at 0OC for
another 20 min and then for 72 h at room tempera-
ture. The solvent was removed in vacuum. Diethyl
ether was added to the residue to precipitate triphen-
ylphosphine oxide, which was filtered off after 24 h.
The filtrate was evaporated, and toluene was added
to the residue to precipitate diisopropyl hydrazinedi-
carboxylate. The obtained precipitate was filtered
off after 48 h. The filtrate was evaporated, and the




White crystals. Yield: 23%; m.p. 157ñ158OC,
lit. 156ñ157OC (14); Analysis: calcd. for C20H20N2O2:
C 74.98, H 6.29, N 8.74%; found: C 74.90, H 5.30,
N 8.76%; TLC: Rf = 0.78 (S2); MS (m/z): 321
[M+H]+; 1H NMR (CDCl3, δ, ppm): 1.55ñ1.71 (m,
piper, 2H), 2.04ñ2.16 (m, piper, 2H), 2.48ñ2.65 (m,
piper, 2H), 2.95ñ3.06 (m, piper, 2H), 3.56 (s, NCH2,
2H), 4.06ñ4.12 (m, CHOH, 1H), 7.22ñ7.40 (m,
arom, 3H), 7.66ñ7.91 (m, arom, 6H).
2-[1-(3-Bromo)benzylpiperidin-4-yl]isoindoline-
1,3-dione (4b)
White crystals. Yield: 22%; m.p. 108ñ113OC;
Analysis: calcd. for C20H19N2O2Br: C 60.16, H 4.80,
N 7.02%; found: C 60.10, H 4.82, N 7.06%; TLC:
Rf: = 0.88 (S2); MS (m/z): 399 [M+H]+; 1H NMR
(CDCl3, δ, ppm): 1.57ñ1.73 (m, piper, 2H),
2.04ñ2.17 (m, piper, 2H), 2.48ñ2.65 (m, piper, 2H),
2.92ñ3.03 (m, piper, 2H), 3.51 (s, NCH2, 2H),
4.06ñ4.20 (m, CHOH, 1H), 7.14ñ7.42 (m, arom,
4H), 7.65ñ7.86 (m, arom, 4H).
2-[1-(3-Chloro)benzylpiperidin-4-yl]isoindoline-
1,3-dione (4c)
White crystals. Yield: 31%; m.p. 96ñ99OC;
Analysis: calcd. for C20H19N2O2Cl: C 67.70, H 5.40,
N 7.89%; found: C 67.74, H 5.43, N 7.86%; TLC: Rf
= 0.95 (S2); MS (m/z): 355 [M+H]+; 1H NMR
(CDCl3, δ, ppm): 1.60ñ1.77 (m, piper, 2H),
2.04ñ2.18 (m, piper, 2H), 2.48ñ2.66 (m, piper, 2H),
2.93ñ3.04 (m, piper, 2H), 3.52 (s, NCH2, 2H),
4.06ñ4.20 (m, CHOH, 1H), 7.20ñ7.40 (m, arom,
4H), 7.63ñ7.88 (m, arom, 4H).
2-[1-(3-Fluoro)benzylpiperidin-4-yl]isoindoline-
1,3-dione (4d)
White crystals. Yield: 17%; m.p. 99OC; TLC:
Rf = 0.90 (S2); Analysis: calcd. for C20H19N2O2F: C
70.99, H 5.66, N 8.25%; found: C 70.90, H 5.62, N
8.26%; MS (m/z): 339 [M+H]+; 1H NMR (CDCl3, δ,
ppm): 1.59ñ1.76 (m, piper, 2H), 2.04ñ2.18 (m,
piper, 2H), 2.48ñ2.65 (m, piper, 2H), 2.93ñ3.04 (m,
piper, 2H), 3.54 (s, NCH2, 2H), 4.06ñ4.21 (m,




White crystals. Yield: 22%; m.p. 131OC.
Analysis: calcd. for C21H22N2O3: C 71.98, H 6.33, N
7.99%; found: C 71.91, H 6.23, N 7.92%; TLC: Rf =
0.67 (S2); MS (m/z): 351 [M+H]+; 1H NMR (CDCl3,
δ, ppm): 1.58ñ1.75 (m, piper, 2H), 2.04ñ2.18 (m,
piper, 2H), 2.48ñ2.66 (m, piper, 2H), 2.95ñ3.07 (m,
piper, 2H), 3.53 (s, NCH2, 2H), 3.83 (s, OCH3, 3H),
4.05ñ4.20 (m, CHOH, 1H), 6.76ñ7.29 (m, arom,
4H), 7.65ñ7.88 (m, arom, 4H).
2-[1-(4-Bromo)benzylpiperidin-4-yl]isoindoline-
1,3-dione (4f)
White crystals. Yield: 30%; m.p. 131OC;
Analysis: calcd. for C20H19BrN2O2: C 60.16, H 4.80,
N 7.02%; found: C 60.18, H 4.70, N 7.01%; TLC: Rf
= 0.82 (S2); MS (m/z): 399 [M+H]+; 1H NMR
(CDCl3, δ, ppm): 1.55ñ1.71 (m, piper, 2H),
2.02ñ2.14 (m, piper, 2H), 2.47ñ2.64 (m, piper, 2H),
2.91ñ3.02 (m, piper, 2H), 3.49 (s, NCH2, arom, 2H),
4.06ñ4.19 (m, CHOH, 1H), 7.21ñ7.48 (m, aromat,
2H), 7.66-7.88 (m, aromat, 6H).
General procedure for the synthesis of com-
pounds 5a-f
To a stirred solution of various substituted 2-
(1-benzylpiperidin-4-yl)isoindoline-1,3-diones
(4a-f) (3 mmol) in methanol (60 mL) hydrazine
hydrate (3 g, 60 mmol) was added dropwise. The
resulting mixture was stirred at room temperature
for 24 h. Then, the obtained white precipitate was
filtered off and washed with methanol. The filtrate
was evaporated, and the remaining oil was dissolved
in water (60 mL) and extracted with dichlorometh-
ane (3 ◊ 60 mL). The combined organic layers were
dried over Na2SO4, filtered, and concentrated in vac-
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uum. The obtained oil was used in further synthesis
without purification.
General procedure for the synthesis of com-
pounds 6añf
CDI (1 eq.) was added to a solution of 1H-
indole-5-carboxylic acid (1 eq. for compounds 5añc
or 1.5 eq for compounds 5dñf) in dry THF under an
atmosphere of dry argon. Thirty minutes later, vari-
ous substituted 4-amine-1-benzylpiperidines (5añf)
(1 eq.) dissolved in THF were added, and the reac-
tion mixture was stirred at room temperature for 24
h. Then, the solvent was removed in vacuum and the
oil obtained was purified by column chromatogra-
phy using an acetone as a solvent.
1H-indole-5-carboxylic acid (1-benzylpiperidin-
4-yl)-amide (6a)
Reagents: 4-amine-1-benzylpiperidine (0.38 g,
2 mmol), 1H-indole-5-carboxylic acid (0.32 g, 2
mmol), CDI (0.32 g, 2 mmol), THF (6 mL). Yellow
semi-solid. Yield: 83%. Analysis: calcd. for
C21H23N3O: C 75.65, H 6.95, N 12.60%; found: C
75.24, H 6.92, N 12.14%; TLC: Rf = 0.51 (S3); MS
(m/z): 334 [M+H]+; 1H NMR (DMSO-d6, δ, ppm):
1.49ñ1.85 (m, piper, 4H), 1.93ñ2.07 (m, piper, 2H),
2.72ñ2.90 (m, piper, 2H), 3.45 (s, NCH2, 2H),
3.68ñ3.87 (m, CHNH, 1H), 6.50 (s, NHCO, 1H),
7.15ñ7.67 (m, arom, 8H), 7.99ñ8.15 (m, arom, 2H),




dine (0.54 g, 2.04 mmol), 1H-indole-5-carboxylic
acid (0.33 g, 2.04 mmol), CDI (0.33 g, 2.04 mmol),
THF (6 mL). Yellow oil. Yield: 59%; TLC: Rf =
0.74 (S3); MS (m/z): 412 [M+H]+; 1H NMR (DMSO-
d6, δ, ppm): 1.50ñ1.67 (m, piper, 2H), 1.72ñ1.83 (m,
piper, 2H), 1.94ñ2.06 (m, piper, 2H), 2.74ñ2.86 (m,
piper, 2H), 3.46 (s, NCH2, 2H), 3.70ñ3.86 (m,
CHNH, 1H), 6.50 (s, NHCO, 1H), 7.23ñ7.63 (m,





dine (0.5 g, 2.26 mmol), 1H-indole-5-carboxylic
acid (0.36 g, 2.26 mmol), CDI (0.36 g, 2.26 mmol),
THF (6 mL). Yellow oil. Yield: 25%; TLC: Rf =
0.82 (S3); MS (m/z): 368 [M+H]+; 1H NMR (DMSO-
d6, δ, ppm): 1.50ñ1.69 (m, piper, 2H), 1.71ñ1.85 (m,
piper, 2H), 1.94ñ2.13 (m, piper, 2H), 2.72ñ2.86 (m,
piper, 2H), 3.48 (s, NCH2, 2H), 3.70ñ3.87 (m,
CHNH, 1H), 6.50 (s, NHCO, 1H), 7.21ñ7.57 (m,





dine (0.65 g, 2.36 mmol), 1H-indole-5-carboxylic
acid (0.57 g, 3.5 mmol), CDI (0.57 g, 3.5 mmol),
THF (6 mL). Yellow oil. Yield: 85%; TLC: Rf 0,80
(S3); MS (m/z): 352 [M+H]+; 1H NMR (DMSO-d6, δ,
ppm): 1.48ñ1.70 (m, piper, 2H), 1.72ñ1.85 (m,
piper, 2H), 1.92ñ2.12 (m, piper, 2H), 2.74ñ2.88 (m,
piper, 2H), 3.48 (s, NCH2, 2H), 3.66ñ3.88 (m,
CHNH, 1H), 6.50 (s, NHCO, 1H), 6.95ñ7.76 (m,





dine (0.4 g, 1.85 mmol), 1H-indole-5-carboxylic
acid (0.46 g, 2.8 mmol), CDI (0.46 g, 2.8 mmol),
THF (6 ml). Yellow oil. Yield: 85%; TLC: Rf 0.80
(S3); MS (m/z): 364 [M+H]+; 1H NMR (DMSO-d6, δ,
ppm): 1.52ñ1.70 (m, piper, 2H), 1.72ñ1.84 (m,
piper, 2H), 1.92ñ2.08 (m, piper, 2H), 2.74ñ2.90 (m,
piper, 2H), 3.43 (s, NCH2, 2H), 3.72 (s, OCH3, 3H),
3.70ñ3.88 (m, CHNH, 1H), 6.51 (s, NHCO, 1H),
7.03ñ7.48 (m, arom, 7H), 8.03ñ8.15 (m, arom, 2H),




dine (0.45 g, 1.7 mmol), 1H-indole-5-carboxylic
acid (0.41 g, 2.6 mmol), CDI (0.41 g, 2.6 mmol),
THF (6 mL). Yellow oil. Yield: 67%; TLC: Rf =
0.74 (S3); MS (m/z): 412 [M+H]+; 1H NMR (DMSO-
d6, δ, ppm): 1.49ñ1.67 (m, piper, 2H), 1.71ñ1.82 (m,
piper, 2H), 1.94ñ2.13 (m, piper, 2H), 2.73ñ2.84 (m,
piper, 2H), 3.43 (s, NCH2, 2H), 3.69ñ3.87 (m,
CHNH, 1H), 6.65 (s, NHCO, 1H), 7.12ñ7.41 (m,
arom, 7H), 8.20ñ8.26 (m, arom, 2H), 11.28 (s, NH
ind, 1H).
AChE/BuChE inhibitory activity
AChE and BuChE inhibitory activities were
evaluated by spectrophotometrical Ellmanís method
(15) using AChE from electric eel and BuChE from
horse serum (2.5 units/1 mL). DNTB, acetylthio-
choline, butyrylthiocholine and the enzymes were
purchased from Sigma Aldrich. The reaction was
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taken place in a final volume of 3.32 mL of 100 mM
phosphate buffer, pH 8.0, containing 0.25 unit of
AChE or BuChE, 0.3 mmol 5,5í-dithio-bis-(2-
nitrobenzoic) acid (DTNB, Ellmanís reagent) and
0.45 mmol acetylthiocholine or butyrylthiocholine
as substrates. The compounds tested were dissolved
in a mixture water/DMSO (9:1) giving 10 mM stock
solution. Each compound was tested at concentra-
Scheme 1. Synthesis of compounds 3añf ñ 6añf. Reagents and conditions: (i) benzyl bromide (2añf), TBAI, K2CO3, acetonitrile, reflux 24
h; (ii) phthalimide, Ph3P, DIAD, THF, 0OC ñ r.t. 72 h; (iii) NH2NH2◊H2O, methanol, r.t. 24 h; (iv) 1H-indole-5-carboxylic acid, CDI, THF,
r.t. 24 h
Table 1. Cholinoesterases inhibitory activity of compounds tested (6añf) measured at concentration 10 µM.
Compound %I AChE ± SEM %I BuChE ± SEM
6a 20.20 ± 0.72 13.45 ± 0.62
6b na 27.94 ± 1.42
6c na 30.06 ± 1.72
6d na 8.60 ± 1.93
6e na 5.39 ± 1.53
6f na na
Tacrinea 
AChE pIC50 BuChE pIC50
7.76 ± 0.02 nM 8.31 ± 0.01 nM
Donepezilb 6.7 nM -
na ñ not active; a ref. (9), b ref. (4)
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tion 10 µM, which was obtained by dissolving
appropriate amount of stock solution in water. Each
measurement has been done in triplicate. The tested
compounds were preincubated with the enzyme for
5 min at 20OC before starting the reaction by adding
a substrate. Enzyme activity was determined by
measuring the absorbance at 412 nm during 5 min
with the Perkin Elmer Lambda 12 spectrometer. As
a reference, sample without inhibitor was used
(100% enzyme activity). The reaction rates were
compared, and the percent of inhibition due to the
presence of the test compounds was calculated.
RESULTS AND DISCUSSION
New N-benzylpiperidine amides derivatives
(6añf) were prepared according to the synthetic
routes shown in Scheme 1. 
The final amides were evaluated for their
inhibitory potencies against AChE (electric eel) and
BuChE (horse serum) using spectrophotometric
method elaborated by Ellman (15). Tacrine was
used as reference compound. In this test, the
sulfhydryl group of acetylthiocholine or butyrylthio-
choline reacts with 5,5í-dithio-bis-(2-nitrobenzoic)
acid (DTBN, Ellmanís reagent) giving a yellow-col-
ored product. Absorbance determined at 412 nm is
the measure of the activity of compounds tested.
Because of the insolubility of compounds in con-
centrations higher than 10 µM of potential
inhibitors, it was not possible to determine IC50.
Therefore, the activities of compounds designed are
expressed as a percentage of enzyme inhibition at 10
µM concentration. The results obtained are present-
ed in Table 1.
It was found that the only one of the com-
pounds tested, i.e., 1-benzylpiperidine amide of 1H-
indole-5-carboxylic acid (6a) was weak, non-selec-
tive inhibitor for both enzymes. Introduction of the
substituent into meta position of the phenyl ring of
the N-benzylpiperidine fragment resulted in selec-
tive BuChE inhibitors. The most active BuChE
inhibitor (30.06% [10 µM]) was amide (6c) having
chlorine atom in the N-benzylpiperidine moiety. 
CONCLUSION 
In summary, the synthesis of substituted N-
benzylamides of 1H-indole-5-carboxylic acid (6añf)
is described. Some of compounds obtained at con-
centration 10 µM were found to possess moderate
inhibitory activity towards BuChE. The results of
biochemical studies suggest that their BuChE
inhibitory activity might depend on the character of
the substituent of the N-benzylpiperidine fragment
of the molecule. 
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